5-溴-1-甲基四唑 | 16681-79-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 中文名称: 5-溴-1-甲基四唑
• 英文名称: 5-bromo-1-methyl-1H-tetrazole
• 英文别名: 5-Brom-1-methyl-tetrazol；5-bromo-1-methyltetrazole
• CAS: 16681-79-1
• 化学式: C₂H₃BrN₄
• 分子量: 162.977
• InChiKey: MPEZKCXHVQSKLO-UHFFFAOYSA-N

物化性质

• 熔点：
  72-74 °C
• 沸点：
  253.7±23.0 °C(Predicted)
• 密度：
  2.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-溴-1-甲基四唑 在 sodium hydroxide 作用下， 生成 1-甲基-2H-四唑-5-酮
  参考文献：
  名称：

  The Methylation of 5-Hydroxytetrazole^1a,1b

  摘要：

  DOI：

  10.1021/ja01583a044
• 作为产物：
  描述：

  1-甲基-1H-四唑 在 N-溴代丁二酰亚胺(NBS) 、 溶剂黄146 作用下， 以31.1%的产率得到5-溴-1-甲基四唑
  参考文献：
  名称：

  [EN] METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS
  [FR] MÉTHODE DE TRAITEMENT À L'AIDE DE MODULATEURS DE L'ACIDE AMINOLÉVULINIQUE SYNTHASE 2 (ALAS2)

  摘要：

  公开号：

  WO2020247819A3

文献信息

• [EN] INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)<br/>[FR] INHIBITEURS DE LA KINASE CYCLINE-DÉPENDANTE 7 (CDK7)
  申请人：SYROS PHARMACEUTICALS INC

  公开号：WO2019143719A1

  公开（公告）日：2019-07-25

  The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and/or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and/or inhibit the transcription of disease-related genes in the patient (or in a biological sample).

  本发明提供了具有此处描述的结构的化合物；其药学上可接受的盐、溶剂化合物、水合物、互变体以及同位素形式；以及含有上述化合物和/或药学组合物的组合物（例如，药物组合物和试剂盒）。还提供了涉及上述化合物和/或药学组合物用于治疗或预防疾病的给药方法和用途。该疾病可以是增生性疾病，例如癌症（例如，血液癌症（例如，白血病或淋巴瘤），脑癌，乳腺癌，黑色素瘤，多发性骨髓瘤或卵巢癌），良性肿瘤，病理性血管生成，或纤维化疾病。尽管该发明的任何方面都不受可能发生的生物事件的限制，但给予此处描述的化合物或其他组合物可能选择性地抑制细胞周期依赖性激酶7（CDK7）的异常表达或活性，并因此在患者（或生物样本）中诱导细胞凋亡和/或抑制与疾病相关基因的转录。
• Metal-assisted reactions—13
  作者：Brendan J. Hussey、Robert A.W. Johnstone、Jan D. Entwistle

  DOI：10.1016/0040-4020(82)80091-4

  日期：1982.1

  Previous work has shown that, after converting phenols into suitable phenolic ethers, the aromatic CH bond of the original phenol can be reductively cleaved heterogeneously to give a CH bond through the use of molecular hydrogen or hydrogen donors together with a transition metal catalyst. The present work provides a method for selectively replacing a phenolic OH group by H in just a few minutes

  先前的工作表明，在将酚转化为合适的酚醚后，可以通过使用分子氢或氢供体以及过渡金属，异质地裂解原始酚的芳族CH键，使其异质裂解，形成CH键。催化剂。与先前使用氢供体所需的2至4小时以及在分子氢所需的压力下的数小时相比，本发明提供了一种在短短几分钟内用H选择性地取代酚式OH基的方法。各种基团均适用于从苯酚制备所需的酚醚，但最好的基团是具有强吸电子性的杂芳族实体。溶剂似乎在这种非均相反应中起着重要作用，并对其机理进行了讨论。
• [EN] HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR DE L'OREXINE DE TYPE PYRROLIDINE ET PIPÉRIDINE HÉTÉROARYLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2021026047A1

  公开（公告）日：2021-02-11

  The present invention is directed to heteroaryl pyrrolidine and piperidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及异芳基吡咯烷和哌啶化合物，它们是促进睡眠素受体的激动剂。本发明还涉及所述化合物在潜在治疗或预防涉及睡眠素受体的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及睡眠素受体的疾病中的用途。
• Tetrazoles, pharmaceutical use and compositions
  申请人：Glaxo Group Limited

  公开号：US04507296A1

  公开（公告）日：1985-03-26

  The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts or hydrates thereof, in which the substituents are defined later in the specification. The compounds show pharmacological activity as selective histamine H.sub.2 -antagonists.

  该发明涉及一般式（I）的化合物及其生理上可接受的盐或水合物，其中取代基在规范中稍后定义。这些化合物显示出作为选择性组织胺H.sub.2-拮抗剂的药理活性。
• [EN] N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS<br/>[FR] DÉRIVÉS DE N2-PHÉNYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE ET LEUR UTILISATION COMME INHIBITEURS DE MPS1
  申请人：CANCER REC TECH LTD

  公开号：WO2015128676A1

  公开（公告）日：2015-09-03

  The present invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1 –also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

  本发明涉及式（I）的化合物，其中R1、R2、R3和R4均如本文所定义。本发明的化合物已知能够通过直接或间接与Mps1激酶本身相互作用来抑制单丝粒体1（Mps1，也称为TTK）激酶的纺锤体检查点功能。具体地，本发明涉及将这些化合物用作治疗和/或预防增殖性疾病，如癌症的治疗剂。本发明还涉及制备这些化合物的方法，以及包含它们的药物组合物。